Thursday, July 3, 2025 7/3/2025

Long-term durability of DENV-specific immunity after vaccination in a dengue-endemic population

Award Number: U01AI179523
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/06/2024
PERIOD OF PERFORMANCE END DATE: 02/28/2029

Group Awards By:

View Award Description

Long-term durability of DENV-specific immunity after vaccination in a dengue-endemic population - Abstract The goal of this FOA is “to improve our understanding of how vaccines against infectious agents lead to durable protective immunity.” This project seeks to address this objective through a detailed characterization of immune responses in the early phase post-vaccination to identify components that distinguish durable from non-durable responses to vaccination with a live attenuated vaccine against dengue virus (DENV). To date, a single dengue vaccine (CYD-TDV) has reached licensure and others have shown promising efficacy data, but there remain important gaps in the safety and efficacy of these vaccines, particularly around the issue of the durability of protective immunity. This project leverages blood samples available from dengue vaccine trials, in particular a longitudinal study of participants from a phase III trial of CYD-TDV that has been ongoing since 2011. The project addresses the overall hypothesis that functional, transcriptomic, and epigenetic profiles of DENV-specific T and B lymphocytes early post-vaccination predict the establishment of long-lasting DENV-specific serologic immunity through the following Specific Aims: 1) Identify T and B cell functional responses to DENV associated with the long-term persistence of binding and neutralizing antibodies after receipt of CYD-TDV; 2) Identify gene expression and epigenetic profile(s) in DENV-specific T and B lymphocytes associated with the persistence of antibodies after receipt of CYD-TDV; and 3) Validate the immunological signature of durable antibody responses in recipients of CYD-TDV and compare this signature to other dengue vaccines and to natural and experimental DENV infection.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $567,169 )
2025	2025	UNIVERSITY OF RHODE ISLAND	75 LOWER COLLEGE RD RM 103	KINGSTON	RI	02881	WASHINGTON	USA	Allergy and Infectious Diseases Research	000	2	3/27/2025	NON-COMPETING CONTINUATION	$567,169
														Subtotal = $567,169

Issue Date FY: 2024 ( Subtotal = $567,169 )
2024	2024	UNIVERSITY OF RHODE ISLAND	75 LOWER COLLEGE RD RM 103	KINGSTON	RI	02881	WASHINGTON	USA	Allergy and Infectious Diseases Research	000	1	3/6/2024	NEW	$567,169
														Subtotal = $567,169

Grand Total All Awards = $1,134,338

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Long-term durability of DENV-specific immunity after vaccination in a dengue-endemic population

Award Number: U01AI179523

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/06/2024

PERIOD OF PERFORMANCE END DATE: 02/28/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer